Management of Post‑Surgical Left Iliac Crest Neuropathic Pain

First‑Line Pharmacologic Therapy

Gabapentinoids are recommended as the initial agents for acute post‑surgical neuropathic pain; start gabapentin 100–300 mg at bedtime or pregabalin 50 mg three times daily and titrate upward every few days to target doses (gabapentin 900–3600 mg/day divided, pregabalin up to 600 mg/day). Adjust dosing for renal impairment. Monitor for somnolence, dizziness, and mental clouding. Evidence: moderate (Mayo Clinic guidelines) [1][2][4][5]6
Pregabalin may be preferred over gabapentin because of more reliable gastrointestinal absorption and simpler titration. Evidence: moderate 4

Tricyclic antidepressants (TCAs) – use nortriptyline or desipramine rather than amitriptyline for better tolerability. Initiate 10–25 mg nightly, increase every 3–5 days to 50–150 mg nightly. Obtain a screening ECG in patients > 40 years and keep dose < 100 mg/day when possible; avoid in patients with cardiac conduction disease or ischemic heart disease. Evidence: moderate [1][2][3][5]6
Serotonin‑norepinephrine reuptake inhibitors (SNRIs) – duloxetine 30 mg daily for 1 week then 60 mg daily; venlafaxine 50–75 mg daily titrated to 75–225 mg daily. Evidence: moderate [1][2][3][5]6

Topical lidocaine 5 % patch can be applied daily to the painful area; it provides minimal systemic absorption and may be combined with systemic agents. Moderate evidence supports its use for localized peripheral neuropathic pain. Evidence: moderate [1][2][3][5]6
Scheduled acetaminophen and non‑steroidal anti‑inflammatory drugs (NSAIDs) are advised when not contraindicated to supply baseline analgesia and produce opioid‑sparing effects. NSAIDs should be used cautiously because of recent nephrectomy and potential renal function compromise. Evidence: moderate [7][8]9
Opioids are reserved for rescue analgesia only, such as acute severe pain or during titration of neuropathic agents; they are not recommended as primary therapy for neuropathic pain. Evidence: moderate [3][7]9

Reassessment timeline – allow 2–4 weeks at target doses for gabapentinoids and SNRIs, and 6–8 weeks (including at least 2 weeks at the highest tolerated dose) for TCAs before judging efficacy. Pain intensity should be recorded regularly using a numerical rating scale. Evidence: moderate [1][2][3][4]
Response criteria –
- Substantial relief: pain ≤ 3/10 with tolerable side effects → continue current regimen.
- Partial relief: pain ≥ 4/10 after an adequate trial → add a second first‑line medication from a different class.
- Inadequate relief: < 30 % reduction at target dose → switch to an alternative first‑line agent. Evidence: moderate [1][2]3

Specialist referral is indicated when (a) trials of single or combined first‑line medications fail, (b) diagnostic uncertainty persists, or (c) pain markedly impairs function despite optimized therapy. Evidence: moderate [1][2]3
Interventional procedures (performed by pain specialists) may include diagnostic/therapeutic nerve blocks; surgical exploration or removal of offending fascial sutures can be considered in selected cases. Evidence: moderate 10

Dose adjustments for renally excreted medications (gabapentin, pregabalin, certain TCAs) are required after nephrectomy to avoid accumulation and toxicity. Evidence: moderate [5][6]1

Avoid routine prophylactic gabapentinoid administration in surgical patients (e.g., hip arthroplasty) because evidence suggests potential adverse effects may outweigh benefits; this caution pertains to prophylaxis, not treatment of established neuropathic pain. Evidence: moderate 7